This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehta, K. Articles by Sahin, A. A. Search for Related Content PubMed PubMed Citation Articles by Mehta, K. Articles by Sahin, A. A.

Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer

Departments of ¹ Experimental Therapeutics, ² Neuro-Oncology, and ³ Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and ⁴ Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan

Purpose: Drug resistance and metastasis pose major impediments in the successful treatment of cancer. We previously reported that multidrug-resistant breast cancer cells exhibit high levels of tissue transglutaminase (TG2; EC 2.3.2.13). Because the drug-resistant and metastatic phenotypes are thought to share some common pathways, we sought to determine whether metastatic breast cancer cells express high levels of TG2.

Experimental Design: The metastatic breast cancer cell line MDA-MB-231 and the sublines derived from it were tested for TG2 expression. Similarly, several sublines derived from an immortal but normal breast epithelial cell line, MCF10A, representing various stages in breast cancer progression were studied for TG2 expression. The primary and nodal tumor samples from 30 patients with breast cancer were also studied for TG2 expression.

Results: The MDA-MB-231 cells expressed high basal levels of TG2. Two clones derived from this cell line, MDA231/cl.9 and MDA231/cl.16, showed a 10- to 15-fold difference in TG2 level. TG2-deficient MDA231/cl.9 cells exhibited higher sensitivity to doxorubicin and were less invasive than were the TG2-sufficient MDA231/cl.16 cells. The MCF10A-derived sublines had increased TG2 expression as they advanced from noninvasive to an invasive phenotype. Importantly, the metastatic lymph node tumors from patients with breast cancer showed significant higher levels of TG2 expression compared with the primary tumors from the same patients.

Conclusions: TG2 expression is up-regulated in drug-resistant and metastatic breast cancer cells, and it can serve as a valuable prognostic marker for these phenotypes.

This article has been cited by other articles:

				A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, H. Wang, J. Y. Fok, D. Koul, J. Abbruzzese, and K. Mehta Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells Clin. Cancer Res., April 1, 2008; 14(7): 1997 - 2005. [Abstract] [Full Text] [PDF]

				U. Akar, B. Ozpolat, K. Mehta, J. Fok, Y. Kondo, and G. Lopez-Berestein Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells Mol. Cancer Res., March 1, 2007; 5(3): 241 - 249. [Abstract] [Full Text] [PDF]

				D.-S. Kim, S.-S. Park, B.-H. Nam, I.-H. Kim, and S.-Y. Kim Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and Nuclear Factor-{kappa}B Inactivation. Cancer Res., November 15, 2006; 66(22): 10936 - 10943. [Abstract] [Full Text] [PDF]

				A. Verma, H. Wang, B. Manavathi, J. Y. Fok, A. P. Mann, R. Kumar, and K. Mehta Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis Cancer Res., November 1, 2006; 66(21): 10525 - 10533. [Abstract] [Full Text] [PDF]

				A. P. Mann, A. Verma, G. Sethi, B. Manavathi, H. Wang, J. Y. Fok, A. B. Kunnumakkara, R. Kumar, B. B. Aggarwal, and K. Mehta Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway. Cancer Res., September 1, 2006; 66(17): 8788 - 8795. [Abstract] [Full Text] [PDF]

				J. Y. Fok, S. Ekmekcioglu, and K. Mehta Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther., June 1, 2006; 5(6): 1493 - 1503. [Abstract] [Full Text] [PDF]